Senate resolution calls on FDA to reverse its policy on estriol
The U.S. Senate, following in the footsteps of the House, has introduced a resolution urging FDA to lift its restrictions on the use of estriol in bioidentical hormone preparation.
The U.S. Senate has now introduced a resolution calling on the Food & Drug Administration to reverse its policy barring estriol from being used in compounded bioidentical hormone replacement therapy. The resolution, S. Con. Res.88, was introduced by Senators John Cornyn (R, Texas) and Jim Bunning (R, Ky.) and follows a similar House resolution, introduced in May. TheInternational Academy of Compounding Pharmacists applauded the new Senate resolution. Meanwhile, the House resolution has gained a total of 32 members of the House as co-sponsors.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
How PBMs Impede Pharmacists’ Ability to Perform Clinical Services | APhA 2025
March 31st 2025Antonio Ciaccia, President of 3 Axis Advisors, led a discussion on pharmacy benefit manager reform and how the inability to pass legislation has led to increased financial hardships in community pharmacy.
